Toxtyper for automated and semi-quantitative screening of drugs consumed in drug consumption rooms
Applications | 2018 | BrukerInstrumentation
Drug consumption rooms play a vital role in reducing health risks associated with illicit drug use by offering a controlled and hygienic environment. Systematic analysis of consumed substances informs public health initiatives and harm reduction strategies. Automated, semi-quantitative screening methods enable rapid assessment of drug purity and adulterants, supporting onsite risk evaluation and user counseling.
This study aimed to implement and evaluate the Toxtyper™ 2.0 workflow for automated qualitative and semi-quantitative analysis of drug residues collected in Frankfurt’s drug consumption rooms. A particular focus was placed on determining the prevalence of heroin, cocaine, and emerging psychoactive substances, as well as common cutting agents and potential health-threatening adulterants.
Sample preparation
Chromatographic and mass spectrometric conditions
Sample set and qualitative findings
Quantitative distribution
Detection limits and linearity
By combining LC-MSⁿ full-scan data with an extensive compound library, the Toxtyper workflow offers rapid, automated screening of diverse drug matrices. It delivers both qualitative profiles and semi-quantitative estimates of active ingredients and adulterants. This approach supports timely harm-reduction interventions in consumption rooms and can be extended to forensic screening of pills, powders, and novel psychoactive substances.
Expanding the compound database to include newly emerging opioids and synthetic stimulants will enhance the method’s relevance. Further validation for forensic quantification could enable legal case support. Integration into mobile laboratories or near-real-time on-site devices may provide immediate risk assessments. Advanced data analytics and open-source reporting frameworks will facilitate broader adoption by harm-reduction services and regulatory bodies.
The Toxtyper™ 2.0 method proved effective for automated qualitative and semi-quantitative analysis of drugs in consumption-room specimens. It accurately characterized heroin and cocaine purity, identified common adulterants, and detected trace opioids. While not yet validated for precise legal quantification, the workflow offers a user-friendly, high-throughput screening tool to inform public health responses and monitor street-level drug composition.
[1] Peter R, Maljers L, Meyer M, Auwärter V, Kempf J. Automated semi-quantitative screening of drugs consumed in drug consumption rooms in Frankfurt, Germany using LC-ion trap-MS. Proceedings of the 66th ASMS Conference on Mass Spectrometry and Allied Topics; San Diego, CA, June 3–7, 2018; TP 169.
LC/MS, LC/MS/MS, LC/IT
IndustriesForensics
ManufacturerBruker
Summary
Significance of the Topic
Drug consumption rooms play a vital role in reducing health risks associated with illicit drug use by offering a controlled and hygienic environment. Systematic analysis of consumed substances informs public health initiatives and harm reduction strategies. Automated, semi-quantitative screening methods enable rapid assessment of drug purity and adulterants, supporting onsite risk evaluation and user counseling.
Objectives and Study Overview
This study aimed to implement and evaluate the Toxtyper™ 2.0 workflow for automated qualitative and semi-quantitative analysis of drug residues collected in Frankfurt’s drug consumption rooms. A particular focus was placed on determining the prevalence of heroin, cocaine, and emerging psychoactive substances, as well as common cutting agents and potential health-threatening adulterants.
Methodology and Used Instrumentation
Sample preparation
- Weighable powder samples were dissolved in acetonitrile (1 mg/mL) and diluted to 2.5 µg/mL in LC eluent for quantification.
- Trace residues from syringes and packaging were rinsed with acetonitrile, reweighed after drying, and analyzed qualitatively.
Chromatographic and mass spectrometric conditions
- LC System: Dionex UltiMate 3000 with Acclaim® RSLC 120 C18 column (2.1×100 mm, 2.2 µm).
- Mobile phase: A = water with 2 mM ammonium formate, 0.1% formic acid, 1% acetonitrile; B = acetonitrile with same additives; gradient 1–95% B over 11 min; flow rate 500 µL/min; injection 2 µL.
- MS System: amaZon speed™ ion trap in positive-ESI mode; full scan (70–800 Da, 32 500 Da/s) and auto MSⁿ (n=3) with scheduled precursor list.
- Software: Toxtyper™ 2.0 database expanded by ~200 designer stimulants and synthetic opioids; DataAnalysis for automated processing.
Main Results and Discussion
Sample set and qualitative findings
- 409 submissions yielded 468 specimens (powders, filters, packaging).
- Heroin detected in 213 samples; cocaine in 166; combined heroin/cocaine in 61; one amphetamine positive; no novel psychoactive substances quantified, though fentanyl traces appeared in two packaging samples.
- Common adulterants: 63% of cocaine samples contained phenacetin; 25% also had levamisole; heroin samples showed acetaminophen, caffeine, opium alkaloids (noscapine, papaverine) and degradation markers (6-MAM, 6-AC).
Quantitative distribution
- Cocaine purity ranged 1–100 wt.% (median ~71 wt.%), aligning with national low-level distribution averages.
- Heroin content ranged 1–58 wt.% (median ~9 wt.%), significantly below seized-drug medians (~45 wt.%).
- Detected ropivacaine (19 wt.%) in one heroin sample upon additional calibration.
Detection limits and linearity
- Calibration curves for heroin, cocaine and coproducts showed R² > 0.99 across 1–120 wt.%. Semi-quantitative one-point calibration correlated strongly with full curves.
- Limits of detection spanned 1.25–200 ng/mL (0.05–0.5 wt.%), enabling identification of potent opioids at trace levels.
Benefits and Practical Applications of the Method
By combining LC-MSⁿ full-scan data with an extensive compound library, the Toxtyper workflow offers rapid, automated screening of diverse drug matrices. It delivers both qualitative profiles and semi-quantitative estimates of active ingredients and adulterants. This approach supports timely harm-reduction interventions in consumption rooms and can be extended to forensic screening of pills, powders, and novel psychoactive substances.
Future Trends and Potential Applications
Expanding the compound database to include newly emerging opioids and synthetic stimulants will enhance the method’s relevance. Further validation for forensic quantification could enable legal case support. Integration into mobile laboratories or near-real-time on-site devices may provide immediate risk assessments. Advanced data analytics and open-source reporting frameworks will facilitate broader adoption by harm-reduction services and regulatory bodies.
Conclusion
The Toxtyper™ 2.0 method proved effective for automated qualitative and semi-quantitative analysis of drugs in consumption-room specimens. It accurately characterized heroin and cocaine purity, identified common adulterants, and detected trace opioids. While not yet validated for precise legal quantification, the workflow offers a user-friendly, high-throughput screening tool to inform public health responses and monitor street-level drug composition.
References
[1] Peter R, Maljers L, Meyer M, Auwärter V, Kempf J. Automated semi-quantitative screening of drugs consumed in drug consumption rooms in Frankfurt, Germany using LC-ion trap-MS. Proceedings of the 66th ASMS Conference on Mass Spectrometry and Allied Topics; San Diego, CA, June 3–7, 2018; TP 169.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Toxtyper: Detection of opioids and prescription drugs at Miami Dade
2017|Bruker|Applications
Toxtyper: Detection of opioids and prescription drugs at Miami Dade Comprehensive detection and identification of prescription analgesics and illicit opioids in postmortem specimens using Toxtyper. Abstract Ongoing evolution of new designer drugs, also known as new psychoactive substances (NPS), requires…
Key words
fentanyl, fentanylhydroxythiofentanyl, hydroxythiofentanylheroin, heroinhomogenate, homogenatetoxtyper, toxtyperbeta, betadade, dadebuprenorphine, buprenorphinepara, paramiami, miamidesproprionyl, desproprionylnaloxone, naloxonemdme, mdmeeddp, eddpanalogs
Removal of Lipids for the Analysis of Toxicological Compounds in Plasma by LC/MS/MS
2016|Agilent Technologies|Applications
Removal of Lipids for the Analysis of Toxicological Compounds in Plasma by LC/MS/MS Enhanced Matrix Removal—Lipid Dispersive Cleanup Application Note Small Molecule, Toxicology Author Abstract Joan Stevens, A convenient analytical method for the determination of toxicological compounds Agilent Technologies, Inc.…
Key words
lipid, lipidtoxicological, toxicologicalemr, emrdispersive, dispersivecounts, countscleanup, cleanupprecipitation, precipitationhydrochloride, hydrochlorideplasma, plasmamatrix, matrixcns, cnsproadifen, proadifenstimulant, stimulantstrychnine, strychnineppt
Detection and semi-quantitative determination of designer benzodiazepines in serum using LC-MSn
2017|Thermo Fisher Scientific|Applications
Detection and semi-quantitative determination of designer benzodiazepines in serum using LC-MSn Benzodiazepines play an important role in forensic toxicology as they are widely prescribed in the treatment of psychiatric disorders and also used as drugs of abuse. In 2012 the…
Key words
benzodiazepines, benzodiazepinessemi, semiquantitative, quantitativetoxtyper, toxtyperdesigner, designeradinazolam, adinazolamlod, lodscreening, screeningserum, serumconcentrations, concentrationsphenazepam, phenazepametizolam, etizolamdesalkylflurazepam, desalkylflurazepamcompounds, compoundstriazolam
Bruker Toxtyper
2020|Bruker|Brochures and specifications
Toxtyper Confident and Comprehensive Screening with Simplicity and Speed Innovation with Integrity Toxtyper Rapid toxicology screening for forensics and clinical research Today's forensic toxicology and clinical research labs are challenged by demands for fast and accurate results, along with lab…
Key words
toxtyper, toxtyperlibrary, librarytoxicology, toxicologynortilidine, nortilidineopipramol, opipramolscreening, screeningpush, pushbruker, brukerpostmortem, postmortemscopolamine, scopolaminetransferable, transferablezaleplon, zaleplondrugs, drugszopiclone, zopicloneatropine